1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Xbrane Biopharma AB

Xbrane Biopharma AB

1.18
EUR
-0.01
(-0.84%)
-0.01EPS
45.49P/E
19.70MMarket Cap
Oct 30Next Earn
Xbrane Biopharma AB
GETTEX:7XB0
(Gettex)

Recent

price

1.18

P/E

ratio

45.49

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
0.01
0.01
0.02
- -
0.43
244.21
0.01
0.04
0.05
0.26
50.41
15.05
9.28
0.22
Revenue per Share
-0.1
-0.12
-0.57
-82.75
-0.89
-28.62
-1.9
-1.41
-0.91
-0.76
-81.95
-27.06
7.74
0.23
Basic EPS, GAAP
-0.11
-0.14
-0.65
-152.79
-0.8
97.53
-1.52
-1.52
-1.43
-1.13
-89.39
-18.9
-23.76
-0.43
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.42
0.3
-0.29
321.77
1.6
176.32
1.17
1.32
1.95
1.75
81.45
17.04
27.21
26.15
Book Value per Share
0.42
0.3
-3.13
144.76
0.45
37.06
0.69
1
1.73
1.33
34.07
3.34
12.82
10.87
Tangible Book Value per Share
21
21
21
- -
50
- -
99
160
208
226
5
10
16
510
Basic Weighted Avg Shares
- -
- -
- -
- -
22
113
1
7
11
58
239
148
152
113
Sales/Revenue/Turnover
-935.06
-1,277.02
-2,658.99
- -
-202.08
-9.27
-29,985
-3,054.79
-1,647.74
-300.81
-129.8
-80.56
-44.72
-45.88
Operating Margin (%)
- -
- -
1
9
4
4
7
7
13
- -
34
36
21
- -
Depreciation Expense
-2
-3
-12
-28
-45
-13
-188
-226
-188
-173
-388
-266
127
119
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-935.02
-1,276.93
-2,732.56
- -
-208.56
-11.72
-31,331.5
-3,187.06
-1,759.04
-298.98
-162.55
-179.76
83.49
104.88
Profit Margin (%)
9
6
-71
38
10
- -
83
185
341
277
135
68
322
221
Working Capital
- -
- -
- -
2
1
- -
6
4
36
29
156
96
58
3
LT Debt
9
6
-6
114
88
83
159
258
432
425
171
209
561
539
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-34.32
- -
- -
-44.42
-15.44
-155.09
-108.39
-54.65
-40.28
-130.21
-140.16
33.08
31.42
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
57
61
LT Borrowings
58
- -
- -
LT Finance Leases
- -
- -
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
204
125
218

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
375
366
322
Cash, Cash Equivalents & STI
87
67
49
Accounts Receivable, Net
7
19
14
Inventories
194
199
175
Total Current Liabilities
53
121
101
Payables & Accruals
- -
- -
- -
ST Debt
- -
57
61
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-168.43%
39.36%
168.85%
Free Cash Flow
-19.66%
25.72%
109.89%
Net Income, GAAP
138.69%
-15.86%
-147.8%
Sales/Revenue/Turnover
- -
153.72%
2.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14
52
16
66
148
2025
93
40
- -
9
152
2026
17
47
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-7.96
-0.05
-0.03
-0.03
-27.06
2025
0.01
0.11
- -
-0.06
7.74
2026
-0.63
-0.55
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Xbrane Biopharma AB (publ) (XBRANE.ST) is a Sweden-based biotechnology company focused on developing and commercializing biosimilars of high-cost biologic drugs to enhance global accessibility for treatments in oncology, ophthalmology, and autoimmune diseases; headquartered in Solna, Stockholm, and founded in 2008, it leverages a proprietary high-yield protein expression platform technology enabling up to 80% cost reductions in biological drug production compared to standard systems. The company's core pipeline includes Ximluci (Xlucane), a ranibizumab biosimilar referencing Lucentis for wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and related eye conditions, which has received European market authorization and is in launch phase with U.S. approval pending; Xdivane, a nivolumab (Opdivo) biosimilar targeting skin, lung, renal cell, head and neck, and bladder cancers in preclinical phase; and Xdarzane, a daratumumab (Darzalex) biosimilar for multiple myeloma, also in preclinical development, addressing reference products with combined peak annual sales exceeding EUR 24 billion. In March 2025, Xbrane entered an agreement to sell its XB003 (Cimzia/certolizumab pegol biosimilar) program and substantial R&D operations, including approximately 40 employees in Solna, to Alvotech for SEK 275 million, a transaction completed in early June 2025 that streamlined the organization to prioritize Ximluci and Xdivane commercialization; additionally, in June 2025, Xbrane partnered with OneSource Specialty Pharma for commercial manufacturing and supply chain support of its biosimilar portfolio, including technology transfer to facilities in Bangalore, India, accompanied by OneSource's investment in a recent funding round. Xbrane operates primarily from Sweden with development facilities in Italy, targets healthcare providers and patients in Europe and emerging markets, and has been listed on Nasdaq Stockholm First North since 2016.